(2)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the first CellFX
procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company's controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company's U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210219005136/en/